F. Lampreia

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

A. Papoila, U. Caixas, E. Monteiro, 2008, British journal of clinical pharmacology.

[Takotsubo Cardiomyopathy: Cause of a Cardiogenic Shock].

A. Godinho, F. Lampreia, I. Marcão, 2015, Acta medica portuguesa.

Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole

F. Lampreia, M. Ilharco, Carla Maravilha Pereira, 2019, IDCases.

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.

U. Caixas, E. Monteiro, S. Pereira, 2006, British journal of clinical pharmacology.

Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of Therapy

U. Caixas, E. Monteiro, S. Pereira, 2008, Therapeutic drug monitoring.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Long-term maraviroc use as salvage therapy in HIV-2 infection.

N. Grilo, U. Caixas, A. Marinho, 2012, The Journal of antimicrobial chemotherapy.

Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

U. Caixas, T. Branco, I. Germano, 2009, British journal of clinical pharmacology.